U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H42O4S
Molecular Weight 474.696
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of LUNACALCIPOL

SMILES

[H][C@@]12CC=C([C@H](C)C\C=C\S(=O)(=O)C(C)(C)C)[C@@]1(C)CCC\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C

InChI

InChIKey=RFQHCLMGLJGZNV-UXXOMSPDSA-N
InChI=1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1

HIDE SMILES / InChI
Lunacalcipol (CTA-018 or MT-2832) is a vitamin D analog having a dual mechanism of action. It inhibits CYP24A1 and induced VDR expression. It was being developed for the treatment of clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease. Lunacalcipol development has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q07973
Gene ID: 1591.0
Gene Symbol: CYP24A1
Target Organism: Homo sapiens (Human)
27.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Phase II Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018). A total of 11 doses of lunacalcipol Injection (180 or 270 µg) given three times per week over 24 days (day 1 to day 24), administered not more often than every other day.
Route of Administration: Parenteral
Name Type Language
LUNACALCIPOL
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
LUNACALCIPOL [USAN]
Common Name English
CTA018
Code English
Lunacalcipol [WHO-DD]
Common Name English
CTA-018
Code English
lunacalcipol [INN]
Common Name English
1,3-CYCLOHEXANEDIOL, 5-((2E)-2-((3AS,7AS)-1-((1R,3E)-4-((1,1-DIMETHYLETHYL)SULFONYL)-1- METHYL-3-BUTEN-1-YL)-3,3A,5,6,7,7A-HEXAHYDRO-7A-METHYL-4H-INDEN-4- YLIDENE)ETHYLIDENE)-4-METHYLENE-, (1R,3S,5Z)-
Common Name English
(5Z,7E,16Z,23E)-(1S,3R)-25-NOR-25-T-BUTYLSULFONYL-9,10-SECO-5,7,10(19),16,23- CHOLESTAPENTAENE-1,3-DIOL
Common Name English
Code System Code Type Description
NCI_THESAURUS
C170140
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
CAS
250384-82-8
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
INN
9241
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
FDA UNII
XN4TL6M50Z
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
DRUG BANK
DB05024
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105705
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
SMS_ID
300000034266
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
USAN
XX-97
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY
PUBCHEM
10672195
Created by admin on Sat Dec 16 17:53:33 GMT 2023 , Edited by admin on Sat Dec 16 17:53:33 GMT 2023
PRIMARY